Most Popular A relaxing intravenous drip that delivers a higher dose of antioxidants for a brighter, refreshed glow from within
These natural products are widely known for their anti-inflammatory and antioxidant properties (Allegra 2019), which may complement traditional therapies by lowering inflammation, restoring hormone balance, and enhancing general health
However, with the growing interest in NAD+ therapy , understanding the ideal NAD dosage per day and frequency is crucial to achieving optimal results while minimizing potential side effects
Potassium citrate and metabolic acidosis in children with epilepsy on the ketogenic diet: a prospective controlled study
Even moderate activity such as a 30-minute daily walk can significantly improve bowel regularity
Jeffrey Flier on GLP-1 drug discovery Jeffrey Flier, former Dean at Harvard Medical School, writes in STAT on How Pfizer ended up passing on my GLP-1 work back in the early 90s. Flier kicks off with Despite extremely promising results, Pfizer, the major funder of the work in alliance with California Biotechnology, abandoned the effort around 1991 after mistakenly concluding that the GLP-1 therapeutic approach was not worth continuing. He states that he is not trying to take credit for the GLP-1 market, rather that the story offers valuable lessons on drug development for pharmaceutical companies, researchers, and the general public alike. The article describes the early stages of drug development and testing from 1987, with Pfizer against an injectable GLP-1 version, and a focus on a way to deliver GLP-1 via transnasal, transcutaneous, or oral administration